Roche's Genentech sues Biogen over additional patent royalties from Tysabri sales
Sundry Photography


Genentech, a unit of Roche (OTCQX:RHHBY), has filed suit in federal court against Biogen (NASDAQ:BIIB) claiming the latter owes additional patent royalties related to sales of multiple sclerosis and Crohn's disease treatment Tysabri (natalizumab).
Genentech contends that Biogen (BIIB) owes royalties for Tysabri it produced before the patents expired, even if the drug was sold after the expiration.

Biogen hasbn't paid any royalties on Tysabri since the patents in question lapsed four years ago, Genentech alleges.
Genentech licensed the patents to Biogen (BIIB) in exchange for a "mid-single-figure" royalty on sales in the US, Reuters reported.
Read why Seeking Alpha contributor Deep Value Ideas views Roche (OTCQX:RHHBF) as a buy.